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Abstract
Aims/hypothesis The aim of this systematic reviewwas to develop core outcome sets (COSs) for trials evaluating interventions for the
prevention or treatment of gestational diabetes mellitus (GDM).
Methods We identified previously reported outcomes through a systematic review of the literature. These outcomes were
presented to key stakeholders (including patient representatives, researchers and clinicians) for prioritisation using a three-round,
e-Delphi study. A priori consensus criteria informed which outcomes were brought forward for discussion at a face-to-face
consensus meeting where the COS was finalised.
Results Our review identified 74 GDMprevention and 116 GDM treatment outcomes, which were presented to stakeholders in round
1 of the e-Delphi study. Round 1 was completed by 173 stakeholders, 70% (121/173) of whom went on to complete round 2; 84%
(102/121) of round 2 responders completed round 3. Twenty-two GDM prevention outcomes and 30 GDM treatment outcomes were
discussed at the consensus meeting. Owing to significant overlap between included prevention and treatment outcomes, consensus
meeting stakeholders agreed to develop a single prevention/treatment COS. Fourteen outcomes were included in the final COS. These
consisted of six maternal outcomes (GDM diagnosis, adherence to the intervention, hypertensive disorders of pregnancy, requirement
and type of pharmacological therapy for hyperglycaemia, gestational weight gain and mode of birth) and eight neonatal outcomes
(birthweight, large for gestational age, small for gestational age, gestational age at birth, preterm birth, neonatal hypoglycaemia,
neonatal death and stillbirth).
Conclusions/interpretation This COS will enable future GDM prevention and treatment trials to measure similar outcomes that
matter to stakeholders and facilitate comparison and combination of these studies.
Trial registration This study was registered prospectively with the Core Outcome Measures in Effectiveness Trials (COMET)
database: http://www.comet-initiative.org/studies/details/686/
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COS Core outcome set
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Introduction
Gestational diabetes mellitus (GDM) is diabetes with onset or
first recognition during pregnancy that was clearly not overt
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diabetes prior to gestation [1]. It affects 18.4 million pregnancies
worldwide annually [2]. GDM is associated with an increased
risk of adverse pregnancy outcomes including pre-eclampsia and
Caesarean delivery for the mother and neonatal hypoglycaemia,
large for gestational age and birth trauma for the infant [3–7].
These offspring are at increased risk of diabetes and obesity [8, 9]
during childhood and adulthood and the mothers have a signifi-
cantly elevated risk of type 2 diabetes [10, 11].
Over the past two decades, the burden of GDM has driven
an increase in randomised trials of interventions for the
prevention and treatment of GDM [12, 13]. However, hetero-
geneity in outcomes reported in these trials makes combining
and comparing results difficult [14]. As a result, evidence
synthesis and meta-analyses become less efficient and the
reliability of evidence to guide healthcare decisions is limited
[15]. One approach to address this lack of uniformity is to
develop a core outcome set (COS) or an agreed set of
outcomes [16]. A COS represents a minimum set of outcomes
that are expected to be measured and reported in all trials in
specific areas of healthcare; however, researchers may report
additional outcomes at their discretion. Typically, COSs are
also suitable for use in relevant clinical audits and observa-
tional studies [17]. The Core Outcome Measures in
Effectiveness Trials (COMET) initiative brings together
current thinking and provides methodological guidance on
this subject [17, 18]. In the field of women’s health, over 50
journals endorse the Core Outcomes in Women’s Health
(CROWN) initiative, which promotes COS development
and effective dissemination of related manuscripts [19].
The aim of this study was to develop COSs for studies
evaluating the effectiveness of interventions for the prevention
or treatment of GDM.
Methods
This study was registered prospectively with the COMET
database (http://www.comet-initiative.org/studies/details/
686/) and a detailed protocol is published [20]. The study
design was guided by the COMET initiative and COS-
STAD recommendations [18, 21]. Ethical approval for the
study was obtained from the Galway University Hospitals
ethics committee.
The study was conducted within three work packages (Fig.
1): (1) a systematic review of the literature to identify previ-
ously reported outcomes; (2) a three-round, web-based, e-
Delphi survey with key stakeholders to prioritise outcomes;
and (3) a consensus meeting to finalise the COS.
Two separate procedures were originally planned and
conducted: one for GDM prevention and one for GDM treat-
ment. However, the results from these separate consensus
procedures were very similar and stakeholders at the consen-
sus meeting decided to produce a single COS for all studies of
GDM prevention or treatment.
Systematic review The search strategy is outlined in the study
protocol. In brief, the following databases were searched for
relevant studies: MEDLINE; Embase; Web of Science;
Cochrane Library; and the Cumulative Index to Nursing and
Allied Health Literature (CINAHL). We included randomised
trials and systematic reviews of randomised trials (with and
without meta-analyses) comparing the effectiveness of phar-
macological and non-pharmacological interventional strate-
gies for both prevention and treatment of GDM. Given the
large number of previously published studies, a pragmatic
approach was taken and the systematic review was performed
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in stages until outcome saturation was reached. In this regard,
the initial search included time limits of publication between
January 2015 and February 2019.
Two reviewers (A.M. Egan and D. Bogdanet) assessed the
titles and abstracts of identified studies independently. Full
texts of studies meeting the inclusion criteria (or where this
was uncertain) were retrieved and consensus was reached on
inclusion status. Studies were divided into those for preven-
tion and those for treatment of GDM. Outcomes were extract-
ed and grouped under three major domains following review
by the study advisory group (see study protocol) [20]: mater-
nal outcomes; neonatal outcomes; and other outcomes.
e-Delphi study We conducted a three-round, e-Delphi study
using SurveyMethods software (www.surveymethods.com,
accessed 16 April 2019). Participants were recruited from
the following groups: (1) women representatives (pregnant
women at risk of GDM, with GDM or women with a history
of GDM); (2) healthcare professionals (professionals who care
for women with GDM); and researchers (researchers and policy
makers with an active interest in GDM).
We sent an e-mail explaining the study and inviting partic-
ipation through an electronic link to the list managers of the
following organisations: International Association of the
Diabetes and Pregnancy Study Groups (IADPSG); Diabetes
Ireland (DI); Irish Endocrine Society (IES); ADA; EASD; the
Irish Midwifery e-Group; and the Diabetic Pregnancy Study
Group (DPSG) of the EASD. We also circulated information
about the study on social media and to women with diabetes
attending antenatal clinics at University Hospital Galway,
Galway, Ireland. Potential participants were invited to forward
the invitation to others whom they regarded as having the
required expertise. An e-mail reminder was sent to anyone
who did not respond after 10 days and again after 14 days.
The round 1 survey included a further explanation of the
study with a consent process and followed with a short ques-
tionnaire that requested participant demographic data includ-
ing the stakeholder group that best represented their profile. It
also presented the outcomes identified in the review and
participants were asked to rate each outcome for GDM
prevention and treatment separately on a nine-point Likert-
scale with higher values representing increased importance
for inclusion in the COS. There was an ‘unable to score’
option that could be selected for each outcome. All outcomes
were accompanied by a plain English explanation.
Participants were invited to submit up to two additional
outcomes for GDM prevention and two additional outcomes
for GDM treatment that they considered important or relevant
for inclusion in the COS [18]. The results from round 1 were
summarised using descriptive statistics and all outcomes were
carried forward to round 2 including additional outcomes that
were suggested by more than one participant.
Participants who completed round 1 were invited to partic-
ipate in round 2. In this second round, participants were
provided with their scores from round 1 and with the distribu-
tion of scores for each outcome per stakeholder group. They
were asked to re-score the outcomes after considering the
information provided from round 1. Outcomes were classified
as ‘consensus in’ (≥70% participants giving scores of 7–9 and
<15% scoring 1–3), ‘consensus out’ (≤50% participants scor-
ing 7–9 in each stakeholder group) or ‘no consensus’
(anything else). All outcomes scored as ‘consensus in’ were
carried forward to round 3. All participants who completed
rounds 1 and 2 were invited to participate in round 3. Again,
participants were provided with their scores from round 2 and
the distribution of scores per stakeholder group. Participants
were asked to re-score the outcomes.
Consensus meeting A face-to-face consensus meeting took
place on 5 September 2019 in Graz, Austria. The aim was to
agree on the final outcomes to be included in the COS. The
meeting was moderated by an experienced chairperson (DD)
who did not vote at the meeting. Outcomes classified as
‘consensus in’ or ‘no consensus’ in the e-Delphi round 3 were
presented at the meeting along with the responses per stake-
holder group. An open discussion took place on each outcome.
There was opportunity to combine or modify individual
outcomes and participants were encouraged to consider wheth-
er each outcome was applicable to GDM treatment or GDM
prevention or both. Participants were then asked to vote on each
outcome as ‘yes’ or ‘no’ for inclusion in the COS. Participants
used Poll Everywhere (www.polleverywhere.com, accessed 16
October 2019) to vote anonymously. An outcome was included
in the final COS when ≥70% participants voted ‘yes’.
Work package 1
A systematic review of the literature 
to identify lists of previously 
reported outcomes in studies of 
GDM prevention and treatment
Work package 2
A three-round e-Delphi study to 
allow key stakeholders to prioritise 
previously reported outcomes
Work package 3
A face-to-face consensus meeting 
to decide on the final COS
Fig. 1 Summary of the study work packages
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Results
Systematic review Electronic supplementary material (ESM)
Fig. 1 includes the PRISMA flow diagram which depicts the
flow of information through the different phases of the
systematic review. A total of 929 potentially relevant studies
were retrieved. Following review of the title and abstract, 225
full text papers were retrieved and assessed. Ninety papers
were excluded following assessment and 135 papers were
included in the review. Of the 135 papers identified, 45 related
to GDM prevention and 90 related to GDM treatment (Fig. 2).
ESM Table 1 lists all included studies. Outcomes from 2017–
2019 studies were indexed initially followed by outcomes
from 2016 and 2015. During extraction of 2015 outcomes,
saturation was reached, with no new additional outcomes
identified during this time period. Extracted outcomes were
reviewed by the study advisory group to ensure removal of
duplicate outcomes, combine similar outcomes and clarify
outcome terminology. Following this, 74 GDM prevention
outcomes and 116 GDM treatment outcomes were listed for
inclusion in round 1 of the e-Delphi Study (ESM Table 2).
e-Delphi studyRound one was completed by 173 stakeholders
(n = 132, 76% female sex; n = 39, 23% male sex; n = 2, 1.0%
did not disclose sex). All participants gave informed consent
prior to participating. There was international distribution of
participants with 27 countries and six continents represented
(ESM Table 3). A total of 69 (40%) respondents were from
Ireland, 20 (12%) were from Canada and 16 (9%) from the
USA. Stakeholders represented three broad categories: patient
representatives (n = 23, 13%); healthcare professionals (n =
116, 67%); and researchers (n = 34, 19%). Within the group
who self-identified as ‘healthcare professionals’, there was
representation from the following disciplines: anaesthesiolo-
gy; midwifery; specialist midwifery; dietetics; endocrinology;
general practice; neonatology; specialist nursing; obstetric
medicine; obstetr ics; paediatr ics; pharmacy; and
physiotherapy.
The round 2 survey again presented the lists of GDM
prevention outcomes and GDM treatment outcomes. One
additional outcome (breastfeeding) was included in the list
of GDM prevention outcomes as it was suggested by more
than one participant in round 1. Round 2 was completed by
70% (121/173) of those who had completed the first survey as
follows: patient representatives, n = 19 (16%); healthcare
professionals, n = 70 (58%); and researchers, n = 32 (26%).
A total of 22 GDM prevention outcomes and 30 GDM
treatment outcomes were classified as ‘consensus in’ and were
carried forward to round 3 (ESM Table 4). Round 3 was
completed by 84% (102/121) of those who had completed
round 2 as follows: patient representatives, n = 16 (16%);
healthcare professionals, n = 56 (55%); and researchers, n =
30 (29%). Following analysis of round 3, all outcomes were
classified as ‘consensus in’ or ‘no consensus’ and therefore all
22 GDM prevention and 30 GDM treatment outcomes were
carried forward to the face-to-face consensus meeting.
Consensus meeting The panel consisted of 23 participants,
representing a variety of countries, who had volunteered to
take part in the e-Delphi study or who had been sampled
purposefully by the study advisory group. The participants
included representatives from each of the three stakeholder
groups: patient representatives (n = 6); healthcare profes-
sionals (n = 10); and researchers (n = 7). In addition to the
non-voting chairperson, there were two administrators respon-
sible for recording the discussion and poll results. ESM
Table 4 outlines the results of the voting at the consensus
meeting for each outcome. Based on the views of the group,
the treatment outcome listed as ‘requirement for pharmacolog-
ical therapy for hyperglycaemia’ was rephrased to ‘require-
ment and type of pha rmaco log ica l the rapy for
hyperglycaemia’ and the treatment outcome listed as ‘perina-
tal mortality’ was changed to ‘neonatal death’. Following the
voting process, 11 outcomes were included in the GDM
prevention COS and 13 were included in the GDM treatment
COS (ESM Table 4). All eight chosen outcomes from the
neonatal domain were identical between the prevention and
treatment COSs. The GDM treatment COS contained two
additional outcomes that were not included in the GDM
prevention COS. These were ‘adherence to the intervention’
and ‘mode of birth’. Following a further discussion and vote,
these outcomes were included in the GDM prevention COS.
Finally, the prevention outcome ‘GDM diagnosis’ was
(appropriately) not included in the GDM treatment COS.
Given the fact that there was agreement on all other outcomes
929 potentially relevant studies were 
retrieved
704 papers were 
excluded following 
title/abstract review
225 full text papers 
were retrieved and 
assessed
GDM prevention papers:
2015–2016 (n=22)
2017–2019 (n=23)
GDM treatment papers:
2015–2016 (n=50)
2017–2019 (n=40)
90 papers were 
excluded following 
assessment
135 papers were 
included in the review
Fig. 2 Selection of studies for systematic review
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between the two COSs, it was decided that a single COS for
the prevention and/or treatment of GDM would be ideal and
would likely increase uptake of the COS.
Text box 1 outlines the final COS, which includes six
maternal and eight neonatal outcomes. The outcome ‘GDM
prevention’ is highlighted as relevant to GDM prevention
studies only.
Discussion
In this study, a global group of key stakeholders agreed on 14
outcomes to form a COS essential for future trials of GDM
prevention or treatment (Table 1). These outcomes are
grouped under two domains including six maternal and eight
neonatal outcomes. Although the COS was developed with a
specific focus on randomised trials, it should be useful for
non-randomised studies and audit in this field [17]. It is antic-
ipated that this COS will improve consistency in outcome
reporting, facilitate data synthesis and increase the quality of
research relevant to GDM prevention and treatment. The
formation of this COS responds to previous calls for the devel-
opment of a COS in this area to reduce research waste and
improve health outcomes for women with GDM [22].
The COMET handbook [18] and the Core Outcome Set–
Standards for Development (COS-STAD) [21] were used to
guide the development of this study and a detailed protocol
was published. The three-step approach involving a systemat-
ic review, e-Delphi survey and consensus meeting has been
used widely in COS development [16, 23, 24]. Given the
extensive body of published literature in the area of GDM
prevention and treatment, the study team used sequential
searching with relatively narrow time limits until outcome
saturation was reached. It was believed that an exhaustive
search of previously reported trials with no time limit would
require extensive resources and would likely be of low yield.
This pragmatic method yielded a comprehensive list with a
total of 190 outcomes available for rating in round 1 of the e-
Delphi study. In this next step of the study, a large and inter-
national group of stakeholders prioritised the identified
outcomes. This method allows participants to have an equal
voice in rating and to suggest additional outcomes for consid-
eration in the next round of the e-Delphi. Participants were
limited to submitting two additional GDM prevention and two
additional GDM treatment outcomes; additional outcomes
were carried forward only if suggested by more than one
stakeholder. Based on prior experience, additional outcomes
are very unlikely to be included in the final COS if suggested
by just one person and we wished to avoid survey fatigue by
extending an already long survey [16, 24]. The consensus
meeting brought together a diverse group including women
representatives, researchers and clinicians of varying back-
grounds. A broad range of viewpoints was heard and the
chairperson facilitated this. Special attention was taken to
ensure that women representatives were given the opportunity
Table 1 Final COS to be included in future GDM prevention and treat-
ment research
Domain Outcome
Maternal outcomes 1. GDM diagnosisa
2. Adherence to the intervention
3. Hypertensive disorders of pregnancy
4. Requirement and type of pharmacological
therapy for hyperglycaemia
5. Gestational weight gain
6. Mode of birth
Neonatal outcomes 1. Birthweight
2. Large for gestational age
3. Small for gestational age
4. Gestational age at birth
5. Preterm birth
6. Neonatal hypoglycaemia
7. Neonatal death
8. Stillbirth
a Relevant to GDM prevention studies only
Final COS to be included in future 
GDM prevention and treatment 
research
Maternal outcomes
1. GDM diagnosis (relevant to GDM prevention 
studies only)
2. Adherence to the intervention
3. Hypertensive disorders of pregnancy
4. Requirement and type of pharmacological therapy 
for hyperglycaemia
5. Gestational weight gain
6. Mode of birth
Neonatal outcomes
1. Birthweight
2. Large for gestational age
3. Small for gestational age
4. Gestational age at birth
5. Preterm birth
6. Neonatal hypoglycaemia
7. Neonatal death
8. Stillbirth
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to take part actively and plain language explanations were
provided for each outcome under discussion. Two healthcare
professionals were charged with providing further explana-
tions on outcomes particularly to women representatives.
This seemed to enhance the participation of the women repre-
sentatives. The use of an anonymous voting system prevented
participants feeling pressurised into voting a specific way
following the group discussion. During the meeting, the
women representatives shared many personal experiences in
order to highlight the real-life impact of a specific outcome,
and this was valued within the group.
The systematic review was limited to English language
publications. This may have introduced a selection bias,
although given the large number of included studies from a
variety of centres internationally the likelihood of missing
important outcomes is low. We did not introduce a qualitative
aspect to the first phase of the study, such as semi-structured
interviews. It may be argued that this could minimise patient
involvement and the number of patient-centred outcomes
included in the e-Delphi study. However, women representa-
tives were included at every stage of the study and were active
participants in the core study group, the study advisory group,
the e-Delphi process (with the opportunity to add additional
outcomes) and the consensus meeting. In addition, outcomes
were only excluded during the e-Delphi stage if ≤50% partic-
ipants scored them as 7–9 in each of the stakeholder groups.
This resulted in more outcomes being brought forward to the
consensus meeting but gave stakeholder representatives the
opportunity to explain their rationale for marking an outcome
highly. We adapted a snowball sampling approach for the e-
Delphi study. This allowed participants to recruit additional
participants but meant that we did not know how many poten-
tial participants actually responded to the survey. However,
we did exceed our specified goal of at least 20 respondents
from each stakeholder group in round 1 [20] and the retention
rates of 70% between rounds 1 and 2 and 84% between rounds
2 and 3 compare well to prior COS studies [15, 16]. The
greatest non-response rate to rounds 2 and 3 were among
healthcare professionals. Interestingly, this group had
formed the majority of participants in round 1. The impli-
cations of this with respect to the final COS is unclear,
although we are reassured that this group still had signifi-
cant representation at each point in the study. While study
participants had a broad range of backgrounds and coun-
tries of residence, developing countries were not well
represented. This may limit generalisability of the study
to these areas of the world and future work should explore
this issue in more detail. Finally, the scope of this study
was to identify ‘what’ and not ‘how’ outcomes should be
collected. There is a published repository of acceptable
definitions relating to diabetes in pregnancy outcomes that
may be referenced by researchers in order to define ‘how’
outcomes can be collected [25].
The issue of presenting one COS applicable to both
GDM prevention and treatment studies was discussed in
detail at the face-to-face meeting and a final decision was
based on an electronic vote that was unanimous in favour
of combining. This approach was recently taken by
COSGROVE study researchers who developed a COS for
prevention and treatment of fetal growth restriction [15].
The next important step will be to ensure effective dissem-
ination and uptake of the COS and it was the group consen-
sus that having one COS, rather than two, would facilitate
this process.
In summary, this is the first study to define a COS in the
area of GDM prevention and treatment. It is anticipated that
these outcomes, considered essential by key stakeholders, are
collected in future trials and will have a positive impact on the
ability to compare and combine studies. This will allow better
assessment of the effect of a specific intervention, particularly
in relation to rare but important outcomes (such as stillbirth
and neonatal death), that individual studies may not be
adequately powered to assess. The authors now call on
funders, researchers and journals to incorporate this COS into
relevant studies with the aim of improving research in the field
of GDM and ultimately outcomes for women with GDM and
their offspring.
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